银屑病或银屑病关节炎患者使用不同生物制剂的心血管和静脉血栓栓塞风险:模拟目标试验分析
该研究采用模拟目标试验设计,基于TriNetX全国队列数据,纳入2014–2022年首次接受生物制剂的32,098例未用过生物制剂的银屑病或PsA患者,比较IL-17i、IL-12/23i、IL-23i与TNFi的MACE和VTE风险。结果显示总体及亚组中均无显著差异,但在合并高脂血症和糖尿病的患者中,新型生物制剂风险低于TNFi。
要点
- 总体人群中,IL-17i、IL-12/23i、IL-23i与TNFi的MACE和VTE风险无显著差异。
- 银屑病或PsA亚组分析中,所有比较均未见MACE或VTE风险显著差异。
- 合并高脂血症和糖尿病者,使用新型生物制剂的MACE和VTE风险低于TNFi。
核心结论
- 在银屑病或PsA患者中,IL-17i、IL-12/23i和IL-23i与TNFi相比未检测到MACE和VTE风险的显著差异。
研究设计与样本
- 模拟目标试验设计,使用TriNetX研究网络的全国队列数据。
- 纳入2014–2022年首次接受生物制剂的未用过生物制剂的银屑病或PsA患者,共32,098例。
- 按首次处方生物制剂分为TNFi队列20,314例、IL-17i队列5,073例、IL-12/23i队列3,573例、IL-23i队列3,138例。
- 建立三个倾向性匹配队列:IL-17i vs TNFi、IL-12/23i vs TNFi、IL-23i vs TNFi。
主要发现
- 总体人群中,各生物制剂间MACE和VTE风险无显著差异。
- 在银屑病或PsA亚组分析中,所有比较均未观察到MACE或VTE风险的显著差异。
- 在合并高脂血症和糖尿病的患者中,使用新型生物制剂(IL-17i、IL-12/23i或IL-23i)的MACE和VTE风险低于使用TNFi者。
临床怎么用
- 研究结果可为医疗保健提供者和患者在临床决策时提供参考。
- 对于合并高脂血症和糖尿病的银屑病或PsA患者,选择新型生物制剂可能较TNFi降低MACE和VTE风险。
局限性
- 数据缺乏银屑病严重程度信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of major adverse cardiovascular events (MACEs) and venous thromboembolic events (VTEs) in patients with psoriatic disease receiving biologics is not fully understood. OBJECTIVES: This study aimed to investigate whether novel biologic therapies (interleukin 17 inhibitor [IL-17i], interleukin 12/23 inhibitor [IL-12/23i], and interleukin 23 inhibitor [IL-23i]) for biologic-naïve patients with psoriasis or psoriatic arthritis (PsA) are associated with differences in the risks of MACE and VTE compared with those with tumor necrosis factor inhibitors (TNFis). METHODS: An emulated target trial was designed by a nationwide cohort using data from the TriNetX Research Network. Biologic-naïve patients with psoriasis or PsA receiving biologics between 2014 and 2022 were enrolled. Treatment groups were determined by patients' first prescription of biologics. Three propensity-matched cohorts were established, namely, IL-17i versus TNFi, IL-12/23i versus TNFi, and IL-23i versus TNFi. The incidence rate and incidence rate ratios were estimated. RESULTS: A total of 32,098 biologic-naïve patients with psoriasis or PsA treated with biologics were included. All enrollees were further categorized into 4 cohorts (20,314 in the TNFi cohort, 5073 in the IL-17i cohort, 3573 in the IL-12/23i cohort, and 3138 in the IL-23i cohort). No significant difference in the risks of MACE and VTE between biologics existed among patients with psoriatic disease. In the subgroup analyses for either psoriasis or PsA, no significant difference in the risks of MACE or VTE was noted among all comparisons in the subgroup. Among patients with preexisting hyperlipidemia and diabetes mellitus, the risks of MACE and VTE among patients using new biologics (IL-17i, IL-12/23i, or IL-23i) were lower than those using TNFi. LIMITATIONS: The data lack psoriasis severity. CONCLUSIONS: Among patients with psoriasis or PsA, no significant risk differences in MACE and VTE were detected between those with IL-17i, IL-12/23i, and IL-23i and those with TNFi. These findings can serve as a reference to health care providers and patients when making clinical decisions, thereby also providing evidence for future pharmacovigilance research.
引用
- Chen TL, Huang JY, Lin HY, et al. Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis. J Am Acad Dermatol. 2024. PMID: 39736358. doi:10.1016/j.jaad.2024.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。